BioAsset Development (US, Private)

BDC developed anti-TNF alpha based local injectable for the treatment of sciatic pain. Company was planning to enter the clinic and was looking for capital and/or for strategic transaction.

Extera functioned as BDC’s corporate development arm to include planning, strategy and support to phase II clinical studies business planning and execution, fund rising from family offices and in-licensing of API. During Phase II studies, Extera facilitated an option-to-buy transaction with Cephalon / Teva resulting an excellent financial return to BDC investors

Cumulative equity financing of $8m, In-licensing agreement and a $130m structured acquisition of BioAsset.